Cost-effectiveness of interferon alfa in chronic myelogenous leukemia

Journal of Clinical Oncology

Volumn 15, Issue 7, 1997, Pages 2673-2682

  Liberato, Nicola L ^a   Quaglini, Silvana ^a   Barosi, Giovanni ^a  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON;

ARTICLE; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; SURVIVAL TIME;

EID: 0030757470     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1997.15.7.2673     Document Type: Article

References (40)

1. Wagner JE, Zahurak M, Piantadosi S, et al: Bone marrow transplantation of chronic myelogenous leukemia in chronic phase: Evaluation of risks and benefits. J Clin Oncol 10:779-789, 1992
2. Gratwohl A, Hermans J, Niederwieser D, et al: Bone marrow transplantation for chronic myeloid leukemia: Long-term results. Bone Marrow Transplant 12:509-516, 1993
3. Beatty PG, Dahlberg S, Mickelson EM, et al: Probability of finding HLA-matched unrelated marrow donors. Transplantation 45:714-718, 1988
4. Hoyle C, Gray R, Goldman J: Autografting for patients with CML in chronic phase: An update. Hammersmith BMT Team LRF Centre for Adult Leukaemia. Br J Haematol 86:76-81, 1994
5. McGlave PB, de Fabritiis D, Deisseroth A, et al: Autologous transplants for chronic myelogenous leukaemia: Results from eight transplant groups. Lancet 343:1486-1488, 1994
6. McGlave P, Bartsch G, Anasetti C, et al: Unrelated donor marrow transplantation therapy for chronic myelogenous leukemia: Initial experience of the National Marrow Donor Program. Blood 81:543-550, 1993
7. Spencer A, Szydlo RM, Brookes PA, et al: Bone marrow transplantation for chronic myeloid leukemia with volunteer unrelated donors using ex vivo or in vivo T-cell depletion: Major prognostic impact of HLA class I identity between donor and recipient. Blood 86:3590-3597, 1995
8. Kloke O, Wandl U, Opalka B, et al: A prospective randomized comparison of single-agent interferon (IFN)-alpha with the combination of IFN-alpha and low-dose IFN-gamma in chronic myelogenous leukaemia. Eur J Haematol 48:93-98, 1992
9. Italian Cooperative Study Group on Chronic Myeloid Leukemia: Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. N Engl J Med 330:820-825, 1994
10. Allan NC, Richards SM, Shepherd PCA: UK Medical Research Council randomised, multicentre trial of interferon-αn1 for chronic myeloid leukaemia: Improved survival irrespective of cytogenetic response. Lancet 345:1392-1397, 1995
11. Ohnishi K, Ohno R, Tomonaga M, et al: A randomized trial comparing interferon-α with busulfan for newly diagnosed chronic myelogenous leukemia in chronic phase. Blood 86:906-916, 1995
12. Freund M, Huber Ch: Interferon alfa has become a standard in the treatment of chronic myelogenous leukemia. Semin Hematol 30:1-5, 1993 (suppl 3)
13. Talpaz M: Use of interferon in the treatment of chronic myelogenous leukemia. Semin Oncol 21:3-7, 1994 (suppl 14)
14. Sonnenberg FA, Beck JR: Markov models in medical decision making: A practical guide. Med Decis Making 13:322-338, 1993
15. Talpaz M, Kantarjian HM, McCredie KB, et al: Clinical investigation of human alpha interferon in chronic myelogenous leukemia. Blood 69:1280-1288, 1987
16. Mughal TI, Goldman JM: Chronic myeloid leukemia: A therapeutic challenge. Ann Oncol 6:637-644, 1995
17. Ozer H, George SL, Schiffer CA, et al: Prolonged subcutaneous administration of recombinant alpha 2b interferon in patients with previously untreated Philadelphia chromosome-positive chronic-phase chronic myelogenous leukemia: Effect on remission duration and survival: Cancer and Leukemia Group B study 8583. Blood 82:2975-2984, 1993
18. Mahon FX, Montastruc M, Faberes C, et al: Predicting complete cytogenetic response in chronic myelogenous leukemia patients treated with recombinant interferon α. Blood 84:3592-3594, 1994 (letter)
19. Schofield JR, Robinson WA, Murphy JR, et al: Low doses of interferon-α are as effective as higher doses in inducing remissions and prolonging survival in chronic myeloid leukemia. Ann Intern Med 121:736-744, 1994
20. Hehlmann R, Heimpel H, Hasford J, et al: Randomized comparison of interferon-α with busulfan and hydroxyurea in chronic myelogenous leukemia. Blood 12:4064-4077, 1994
21. Kantarjian HM, Smith TL, O'Brien S, et al: Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-α therapy. Ann Intern Med 122:254-261, 1995
22. + chronic myeloid leukemia. Clinical and cytogenetic results at 2 years in 322 patients. Haematologica 77:204-214, 1992
23. Hehlmann R, Heimpel H, Hasford J, et al: Randomized comparison of busulfan and hydroxyurea in chronic myelogenous leukemia: Prolongation of survival by hydroxyurea. Blood 82:398-407, 1993
24. Freund M, von Wussow P, Diedrich H, et al: Recombinant human interferon (IFN) alpha-2b in chronic myelogenous leukaemia: Dose dependency of response and frequency of neutralizing anti-interferon antibodies. Br J Haematol 72:350-356, 1989
25. Morra E, Alimena G, Lazzarino M, et al: Evolving modalities of treatment with interferon alfa-2b for Ph1-positive chronic myelogenous leukaemia. Eur J Cancer 27:S14-S17, 1991 (suppl 4)
26. Thaler J, Gastl G, Fluckinger T, et al: Treatment of chronic myelogenous leukemia with interferon alfa-2c: Response rate and toxicity in a phase II multicenter study. Semin Hematol 30:17-19, 1993 (suppl 3)
27. Wetzler M, Kantarjian H, Kurzrock R, et al: Interferon-α therapy for chronic myelogenous leukemia. Am J Med 99:402-411, 1995
28. Dutcher JP, Eudey L, Wiernik PH, et al: Phase II study of mitoxantrone and 5-azacytidine for accelerated and blast crisis of chronic myelogenous leukemia: A study of the Eastern Cooperative Oncology Group. Leukemia 6:770-775, 1992
29. Bauduer F, Delmer A, Blanc MC, et al: Treatment of chronic myelogenous leukemia in blast crisis and in accelerated phase with high- or intermediate-dose cytosine arabinoside and amsacrine. Leuk Lymphoma 10:195-200, 1993
30. Wong JB, Koff RS, Tinè F, et al: Cost-effectiveness of interferon-α2b treatment for hepatitis B e antigen-positive chronic hepatitis B. Ann Intern Med 122:664-675, 1995
31. Kattan MW, Inoue Y, Giles FJ, et al: Cost-effectiveness of interferon-α and conventional chemotherapy in chronic myelogenous leukemia. Ann Intern Med 125:541-548, 1996
32. Brodin H, Stafelt AM: Treating acute leukaemias - A venture into economic uncertainty? A method for estimating the cost of treating patients with acute myelocytic leukaemia. Acta Oncol 32:501-505, 1993
33. Tennvall GR, Persson U, Nilsson B: The economic costs of acute myeloid leukemia in Sweden. Int J Technol Assess Health Care 10:683-694, 1994
34. Keeler EB, Cretin S: Discounting of life-saving and other nonmonetary effects. Manage Sci 29:300-306, 1983
35. Eisenberg JM: Clinical economics. A guide to the economic analysis of clinical practices. JAMA 262:2879-2886, 1989
36. Mark DB, Hlatky MA, Califf RM, et al: Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction. N Engl J Med 332:1418-1424, 1995
37. Nease RF Jr, Owens DK: A method for estimating the cost-effectiveness of incorporating patient preferences into practice guidelines. Med Decis Making 14:382-392, 1994
38. Giralt S, Kantarjian H, Talpaz M: The natural history of chronic myelogenous leukemia in the interferon era. Semin Hematol 32:152-158, 1995
39. Read JL, Quinn RJ, Berwick DM, et al: Preferences for health outcomes: Comparison of assessment methods. Med Decis Making 4:315-329, 1984
40. Spencer A, O'Brien SG, Goldman JM: Options for therapy in chronic myeloid leukemia. Br J Haematol 91:2-7, 1995